论文部分内容阅读
目的:探究双歧杆菌三联活菌胶囊联合三联疗法治疗幽门螺旋杆菌(Hp)相关性胃炎的价值。方法:选取我院2015年3月-2017年3月期间收治的慢性胃炎伴幽门螺旋杆菌感染患者42例作为本次研究的对象,设为对照组,采用标准三联疗法进行治疗,并将同期收治的另外42例胃炎伴幽门螺旋杆菌感染患者设为研究组,实施双歧杆菌三联活菌胶囊联合三联疗法进行治疗,比较组间疗效。结果:在经过治疗干预后,研究组患者的临床症状改善情况显著优于对照组,而胃镜下黏膜治疗效果相比较对照组更佳;Hp根除率相比较对照组更高;治疗后不良反应发生情况显著低于对照组,组间对比差异显著(P<0.05)。结论:在幽门螺旋杆菌相关性胃炎患者中采用双歧杆菌三联活菌胶囊联合三联疗法进行治疗,不仅可以取得良好疗效,而且不良反应发生率较低,安全性较高,能够有效根除幽门螺旋杆菌,改善患者的胃黏膜损伤,值得在临床上进一步推广及应用。
Objective: To investigate the value of Bifidobacterium triple viable capsule combined with triple therapy in the treatment of Helicobacter pylori-associated gastritis. Methods: Forty-two patients with chronic gastritis and Helicobacter pylori infection who were admitted to our hospital from March 2015 to March 2017 were selected as the control group, treated with standard triple therapy and treated with concurrent triple therapy Of the other 42 patients with gastritis with Helicobacter pylori infection were selected as the study group. Bifidobacterium triple viable capsule combined with triple therapy was administered to compare the efficacy of the two groups. Results: After treatment intervention, the improvement of clinical symptoms of the study group was significantly better than that of the control group, while the endoscopic mucosal treatment effect was better than the control group; Hp eradication rate was higher than that of the control group; adverse reactions occurred after treatment The situation was significantly lower than the control group, significant difference between the groups (P <0.05). Conclusion: The treatment of patients with Helicobacter pylori-associated gastritis with Bifidobacterium triple viable capsule combined with triple therapy not only achieves good curative effect, but also has a lower incidence of adverse reactions and higher safety, which can effectively eradicate helicobacter pylori , To improve gastric mucosal injury in patients, it is worth further clinical application and application.